Von Willebrand factor-a new target for TTP treatment?

New England Journal of Medicine

Volumn 374, Issue 6, 2016, Pages 583-585

  Veyradier, Agnès ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPLACIZUMAB; GLYCOPROTEIN IB; PLACEBO; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; FIBRINOLYTIC AGENT; NANOBODY;

ANTIBODY SPECIFICITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-DOMAIN ANTIBODIES; VON WILLEBRAND FACTOR;

EID: 84959308771     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1515876     Document Type: Editorial

References (10)

1. Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2015; 2015: 631-6.
2. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
4. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
5. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-97.
6. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
7. Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P. Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur J Intern Med 2015; 26: 659-65.
8. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood 2015; 125: 3860-7.
9. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120: 3603-10.
10. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374:511-22.